Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan 16;105(2):141-8.
doi: 10.1093/jnci/djs494. Epub 2012 Dec 20.

Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2

John R McLaughlin  1 , Barry Rosen, Joel Moody, Tuya Pal, Isabel Fan, Patricia A Shaw, Harvey A Risch, Thomas A Sellers, Ping Sun, Steven A Narod
Affiliations

Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2

John R McLaughlin et al. J Natl Cancer Inst. .

Abstract

Background: Studies have suggested that the 5-year survival of women with ovarian cancer and a BRCA1 or BRCA2 mutation is better than expected. We sought to evaluate the impact of carrying a BRCA1 or BRCA2 mutation on long-term survival of women after a diagnosis of invasive ovarian cancer.

Methods: One thousand six hundred twenty-six unselected women diagnosed with invasive ovarian cancer in Ontario, Canada, or in Tampa, Florida, between 1995 and 2004 were followed for a mean of 6.9 years (range = 0.3 to 15.7 years). Mutation screening for BRCA1 and BRCA2 revealed mutations in 218 women (13.4%). Left-truncated survival analysis was conducted to estimate ovarian cancer-specific survival at various time points after diagnosis for women with and without mutations.

Results: In the 3-year period after diagnosis, the presence of a BRCA1 or BRCA2 mutation was associated with a better prognosis (adjusted hazard ratio = 0.68, 95% confidence interval [CI] = 0.48 to 0.98; P = .03), but at 10 years after diagnosis, the hazard ratio was 1.00 (95% CI = 0.83 to 1.22; P = .90). Among women with serous ovarian cancers, 27.4% of women who were BRCA1 mutation carriers, 27.7% of women who were BRCA2 carriers, and 27.1% of women who were noncarriers were alive at 12 years past diagnosis.

Conclusion: For women with invasive ovarian cancer, the short-term survival advantage of carrying a BRCA1 or BRCA2 mutation does not lead to a long-term survival benefit.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Ten-year survival of ovarian cancer patients by BRCA mutation.
Figure 2.
Figure 2.
Ten-year survival of ovarian cancer patients by histology.
Figure 3.
Figure 3.
Ten-year survival of ovarian cancer patients by BRCA mutation, serous cancer only.
Figure 4.
Figure 4.
Ten-year survival of ovarian cancer patients by BRCA mutation, stage III cancer only.
Figure 5.
Figure 5.
Annualized probability of death among ovarian cancer patients according to carriage of a BRCA1 or BRCA2 mutation vs noncarriage.
See this image and copyright information in PMC

References

    1. Engel J, Eckel R, Schubert-Fritschle G, et al. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur J Cancer. 2002; 38: 2435–2445 - PubMed
    1. Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011; 121:(2):353–357 - PubMed
    1. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005; 104:(12):2807–2816 - PubMed
    1. Pal T, Permuth-Wey J, Kapoor R, Cantor A, Sutphen R. Improved survival in BRCA2 carriers with ovarian cancer. Fam Cancer. 2007; 6(12): 113–119 - PMC - PubMed
    1. Pharoah PD, Easton DF, Stockton DL, Gayther S, Ponder BA. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res. 1999; 59:(4):868–871 - PubMed

Publication types

MeSH terms